Plasmodium vivax is a species of the genus Plasmodium that causes vivax malaria in humans. It is one of the five species of Plasmodium that infect humans, along with Plasmodium falciparum, Plasmodium malariae, Plasmodium ovale, and Plasmodium knowlesi. P. vivax is responsible for the majority of malaria cases outside of Africa and is considered to be one of the most widespread and clinically significant human malaria parasites globally. Symptoms of vivax malaria include fever, chills, headache, muscle pain, and fatigue, and can be treated with antimalarial medications such as chloroquine or primaquine.
types of plasmodium vivex
life cycal of plasmodium vivex
The life cycle of Plasmodium vivax, like other species of Plasmodium, involves both a vertebrate host (in this case, humans) and an invertebrate host (the female Anopheles mosquito).
The life cycle begins when a female Anopheles mosquito takes a blood meal from an infected human. The mosquito ingests sporozoites, the infective form of the parasite, which then migrate to the mosquito's salivary glands.
When the mosquito takes its next blood meal, it injects sporozoites into the human host through its saliva.
The sporozoites quickly migrate to the liver, where they multiply and differentiate into merozoites, another stage of the parasite.
The merozoites are released from the liver into the bloodstream and infect red blood cells, where they multiply and cause the characteristic symptoms of vivax malaria.
Some of the merozoites differentiate into sexual stage forms called gametocytes.
The mosquito takes another blood meal from an infected human and ingests gametocytes. Inside the mosquito's gut, male and female gametocytes fuse to form a zygote, which then develops into an ookinete.
The ookinete burrows through the mosquito's gut wall and develops into an oocyst.
Inside the oocyst, the parasite undergoes further development, producing many sporozoites.
The oocyst ruptures, releasing the sporozoites into the mosquito's haemocoel, the body cavity that contains the blood vessels.
The sporozoites migrate to the mosquito's salivary glands, completing the life cycle and preparing for transmission to another human host.
It's worth noting that Plasmodium vivax has a dormant stage called hypnozoites, which are liver forms of the parasite that can remain dormant for several months to several years before reactivating and causing a new episode of malaria.
thyrapy
Treatment of Plasmodium vivax malaria typically involves the use of antimalarial medications to clear the parasite from the bloodstream and prevent complications. The most common drugs used to treat vivax malaria include:
Chloroquine: This is the first-line treatment for vivax malaria in most areas. It is relatively inexpensive, well-tolerated, and effective against both the blood stages and liver stages of the parasite.
Artemisinin-based combination therapies (ACTs): These are recommended as an alternative to chloroquine in areas where chloroquine resistance is known or suspected. ACTs combine an artemisinin derivative (such as artesunate or artemether) with a longer-acting partner drug (such as mefloquine, lumefantrine, or amodiaquine) to improve efficacy and prevent the development of resistance.
Primaquine: This drug is effective against the dormant liver stages of the parasite (hypnozoites) and is typically used in combination with other antimalarials (such as chloroquine or ACTs) to prevent relapses.
Other medications like doxycycline and atovaquone/proguanil have been used to treat P. vivax malaria but are not considered first-line treatment.
It's important to note that the appropriate treatment regimen for P. vivax malaria will depend on a number of factors, including the patient's age, pregnancy status, and underlying health conditions, as well as the local drug resistance patterns and availability of medications. It's recommended to consult with a healthcare professional for a proper diagnosis and treatment plan.
0 Comments